Lobbying Information
Subject Matters
- Aboriginal Affairs
- Agriculture
- Arts and Culture
- Broadcasting
- Constitutional Issues
- Consumer Issues
- Defence
- Education
- Employment and Training
- Energy
- Environment
- Financial Institutions
- Fisheries
- Forestry
- Government Procurement
- Health
- Immigration
- Industry
- Infrastructure
- Intellectual Property
- Internal Trade
- International Relations
- International Trade
- Justice and Law Enforcement
- Labour
- Mining
- Regional Development
- Science and Technology
- Small Business
- Sports
- Taxation and Finance
- Telecommunications
- Tourism
- Transportation
Subject Matter Details
Legislative Proposal, Bill or Resolution
- Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry
- Canada's Food and Consumer Safety Action Plan (formerly C-51) as it relates to the regulation and protection of biopharmaceutical products
- Income Tax Act as it relates to biopharmaceutical products
- Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
Legislative Proposal, Bill or Resolution, Regulation
- Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies
- Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals
Policies or Program
- Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Acess to Medicines, and TRIPs "flexibility"
- Anti-Counterfeit Trade Agreement (ACTA) as it concerns counterfeit drugs
- Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease
- Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships
- Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework
- Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH)
- Free trade treaty agreement as it relates to the North American Free Trade Agreement (NAFTA) and free trade negotiations as it relates to Columbia, India, and the European Union
- Health Canada's Progressive licensing framework as it relates to the review and approval of biopharmaceutical products
- National Pharmaceutical Strategy as it relates to the federal government's involvement in federal/provincial access to medicines framework
- Pharmaceutical pricing policy arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
- Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits
- Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations
- The government's Science and Technology Strategy potential policies & programs pertaining to the biopharmaceutical industry
- World Health Organization Policies concerning pharmaceuticals with regard to Counterfeits, Access to Medicines, and the Intergovernmental Working Group (IGWG)
Regulation
- Food and Drug Regulations as it relates to data protection.
- Food and Drug Regulations as it relates to regulation and protection of biopharmaceutical products
- New Substances Notification Regulations as it relates to the biopharmaceutical industry
- Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
- Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive
- Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products
- Smart Regulations as it relates to the biopharmaceutical industry
Communication Techniques
-
Written communication
-
Oral communication
The lobbyist has arranged or expects to arrange one or more meetings on behalf of the client between a public office holder and any other person in the course of this undertaking.
Government Institutions
-
Agriculture and Agri-Food Canada (AAFC)
-
Canadian Agency for Drugs and Technologies in Health (CADTH)
-
Canadian Institutes of Health Research (CIHR)
-
Canadian International Development Agency (CIDA)
-
Canadian International Trade Tribunal (CITT)
-
Competition Tribunal (CT)
-
Environment Canada
-
Finance Canada (FIN)
-
Foreign Affairs and International Trade Canada (DFAITC)
-
Health Canada (HC)
-
Industry Canada
-
Justice Canada (JC)
-
Members of the House of Commons
-
National Research Council (NRC)
-
Natural Sciences and Engineering Research Council (NSERC)
-
Office of the Information and Privacy Commissioner (OIPC)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Public Health Agency of Canada (PHAC)
-
Public Works and Government Services Canada
-
Revenue Canada (RC)
-
Senate of Canada
-
Solicitor General Canada (SGC)
-
Statistics Canada (StatCan)
-
Treasury Board Of Canada Secretariat (TBS)
-
Veterans Affairs Canada (VAC)
Client Details
Government funding
No government funding was received during the last completed financial year.
Client Contact Information
Address:
1220-55 Metcalfe St.
Ottawa, ON K1P 6L5
Canada
Telephone number:
613-236-0455
Fax number:
613-236-7919
Client representative
Normand Laberge, Vice President, Federal Affairs and Federal, Provincial &Territorial Relations
Parent Company Information
Canada's Research -Based Pharmaceutical Companies Rx&D is not a subsidiary of any other parent companies.
Coalition Members Information
Canada's Research -Based Pharmaceutical Companies Rx&D is not a coalition.
Individual, organization or corporation with a Direct Interest Beneficiary Information
The activities of Canada's Research -Based Pharmaceutical Companies Rx&D are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
Subsidiary Beneficiary Information
Canada's Research -Based Pharmaceutical Companies Rx&D does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyist Details
ANDRE ALBINATI
|
Public offices held
Business address:
Suite 200, 46 Elgin Street
OTTAWA, ON K1P 5K6
Canada
Telephone number:
613-563-4455
Fax number:
613-236-6173
Consultant Firm and Address
Firm:
Earnscliffe Strategy Group
Address:
Suite 200, 46 Elgin Street
OTTAWA, ON K1P 5K6
Canada
Telephone number:
613-563-4455
Fax number:
613-236-6173
